Abstract
New concept, “molecular markers”, is introduced into the field of blood coagulation and fibrinolysis. An approach to make the pathological states of DIC clear using laboratory tests for molecular markers must be useful on the diagnosis and treatment of DIC. In this paper, the detection of crosslinked fibrin degradation products (XL FDP) with monoclonal antibodies and of α2 plasmin inhibitor-plasmn complex (α2 PI·Plm complex) by ELISA with differential antibodies are described. Both XL FDP and α2 PI·Plm complex are markedly elevated in patients with DIC. Elevation of XL FDP in DIC suggests that the crosslinking reaction has occured prior to the fibrinolysis of non-crosslinked fibrin. α2 PI·Plm complex assay will be helpful to differentiate the increased consumption and the decreased production state. These tests for molecular markers will give us a lot of informations for not only the basic analysis of DIC but also the clinical practise.
